DUBLIN--(BUSINESS WIRE)--The "Hypoparathyroidism: Drug Development Pipeline Study, H1 2018" report has been added to ResearchAndMarkets.com's offering.
The most comprehensive pipeline review Hypoparathyroidism- Drug Development Pipeline Study provides in-depth analysis and update information on Hypoparathyroidism pipeline drugs. Current status of all the drugs in the Hypoparathyroidism pipeline is provided in the research work.
The report provides detailed analysis of Hypoparathyroidism pipeline including companies involved, drugs in different stages of development, drug development details across regions (North America, Europe, Asia Pacific and Rest of the World). Further, the Hypoparathyroidism report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Hypoparathyroidism industry.
Excerpts from - Hypoparathyroidism - Drug Development Pipeline Study:
Hypoparathyroidism pipeline comprises of 6 drugs under development as of February 2018. Of these, 3 drugs are in Phase 1 and 1 drug is in phase 2. Further, 2 drugs remain in Pre-clinical stage. One drug has been discontinued.
7 companies/institutions are developing the pipeline for Dravet Sysndrome. Of this, Chugai Pharmaceuticals is developing the most drugs. On the other hand, recombinant human Parathyroid Hormone (rhPTH [1-84]/ Natpar) of Shire Plc has been approved during H1 2017.
2 drugs have been assigned with orphan drug designation.
Hypoparathyroidism is relatively rare form of thyroid disorders, expected to affect around 70,000 people in the US and 260,000 people in the EU. The disease is caused when parathyroid glands fails to produce PTH (parathyroid hormone). It leads to abnormal calcium levels in the body and is not treated by hormone replacement.
The primary cause of failure of the parathyroid glands is often removal of parathyroid glands by surgery. Though rarely, family history, congenital diseases or auto-immune diseases can cause failure of the glands. Around78% of the instances is caused by surgery while 7% occurs due to family history and idiopathic (6%).
- Hemoparatide (hPTH 1-37)
- PCO 371
- PTH-1-34 - Entera Bio
- recombinant human Parathyroid Hormone (rhPTH [1-84])
Key Topics Covered:
1 List of Figures & Tables
2 Executive Summary
3 Hypoparathyroidism- Company Wise Pipeline Analysis
4 Hypoparathyroidism Drug Snapshots
5 Recent Developments in Hypoparathyroidism Pipeline
- Ascendis Pharma A/S
- Chugai Pharmaceutical Co Ltd
- Eli Lilly and Co
- Entera Bio Ltd
- Pharis Biotec GmbH
- Shire Plc
- IPF PharmaCeuticals
- Pharis Biotec
- NPS Pharmaceuticals
- Takeda Pharmaceuticals International GmbH
For more information about this report visit https://www.researchandmarkets.com/research/bl72p4/hypoparathyroidism?w=4